HDIM
GCVRZ

Hanson & Doremus Investment Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Hanson & Doremus Investment Management’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-30
Closed – – 465
2016
Q2 		$0 Hold
30
– – ﹤0.01% 482
2016
Q1 		$0 Hold
30
– – ﹤0.01% 496
2015
Q4 		$0 Hold
30
– – ﹤0.01% 493
2015
Q3 		$0 Hold
30
– – ﹤0.01% 473
2015
Q2 		$0 Buy
+30
New +$21 ﹤0.01% 472
2014
Q3 		– Sell
-30
Closed – – 432
2014
Q2 		$0 Buy
+30
New +$15 ﹤0.01% 429

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.82% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BHMP
Bardin Hill Management Partners New York $80.3M AUM 31.37% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Hanson & Doremus Investment Management's GCVRZ Position: Q3 2016 in Review

Hanson & Doremus Investment Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2016, closing a stake of 30 shares.

Hanson & Doremus Investment Management first reported a position in GCVRZ in Q2 2014 and held it in 6 quarters. The position peaked at $0 in Q2 2016. 116 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2016.

  • Hanson & Doremus Investment Management reported no remaining Sanofi Contingent Value Rights position as of Q3 2016 after selling out during the quarter.
  • Hanson & Doremus Investment Management sold 30 Sanofi Contingent Value Rights shares in Q3 2016.
  • Hanson & Doremus Investment Management first reported a position in Sanofi Contingent Value Rights in Q2 2014 and held it in 6 quarters.
  • Hanson & Doremus Investment Management's Sanofi Contingent Value Rights position peaked at $0 in Q2 2016.
  • 116 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2016.

Based on Hanson & Doremus Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.